KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

GoodRx Holdings (GDRX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to 7.46%.

  • GoodRx Holdings' EBITDA Margin fell 29900.0% to 7.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.37%, marking a year-over-year increase of 66500.0%. This contributed to the annual value of 8.88% for FY2024, which is 118400.0% up from last year.
  • GoodRx Holdings' EBITDA Margin amounted to 7.46% in Q3 2025, which was down 29900.0% from 13.2% recorded in Q2 2025.
  • Over the past 5 years, GoodRx Holdings' EBITDA Margin peaked at 13.2% during Q2 2025, and registered a low of 21.3% during Q3 2023.
  • Over the past 5 years, GoodRx Holdings' median EBITDA Margin value was 5.51% (recorded in 2021), while the average stood at 2.98%.
  • Within the past 5 years, the most significant YoY rise in GoodRx Holdings' EBITDA Margin was 2005300bps (2021), while the steepest drop was -358500bps (2021).
  • Quarter analysis of 5 years shows GoodRx Holdings' EBITDA Margin stood at 5.51% in 2021, then tumbled by -83bps to 0.94% in 2022, then plummeted by -1086bps to 9.3% in 2023, then soared by 198bps to 9.15% in 2024, then fell by -19bps to 7.46% in 2025.
  • Its EBITDA Margin was 7.46% in Q3 2025, compared to 13.2% in Q2 2025 and 11.52% in Q1 2025.